{"name":"Sang Gyune Kim","slug":"sang-gyune-kim","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Daclatasvir and Asunaprevir","genericName":"Daclatasvir and Asunaprevir","slug":"daclatasvir-and-asunaprevir","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1b","status":"phase_2"}]}],"pipeline":[{"name":"Daclatasvir and Asunaprevir","genericName":"Daclatasvir and Asunaprevir","slug":"daclatasvir-and-asunaprevir","phase":"phase_2","mechanism":"Daclatasvir and Asunaprevir are direct-acting antivirals that inhibit the HCV NS5A and NS3/4A proteases, respectively.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1b"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE50WDhVX2FtLVR5MUU5djVZbXpQWjE3OGhHdk9uczRsOXYxcVV1SzRTWXkzYVdHMF9vblhLWVBjOGJfRWZpVDE3cDM5V3ZUT2NpQ29JU0FZeFYtRGo3azVN?oc=5","date":"2025-08-29","type":"pipeline","source":"Nature","summary":"Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B - Nature","headline":"Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}